Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, accountable care organizations (ACOs) and direct contract entities (DCEs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provides insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company’s services primarily are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum.
During the most recent quarter, 60 shares were bought, and 454K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.